Jul 22 |
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
|
Jul 17 |
Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
|
Jul 15 |
Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs
|
Jul 15 |
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
|
Jul 12 |
Biggest stock movers today: WFC, TSLA, ERIC, and more
|
Jul 12 |
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
|
Jul 12 |
Immutep gains after positive results from cancer trial
|
Jul 11 |
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
|
Jul 3 |
Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results
|
Jun 28 |
Prima BioMed (IMMP) Loses -34.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|